<DOC>
	<DOCNO>NCT02111031</DOCNO>
	<brief_summary>The objective registry study demonstrate clinical utility CELLSEARCH® CTC Test among Medicare-Eligible metastatic Breast Cancer ( mBC ) patient United States . The objective present registry demonstrate impact patient management CELLSEARCH® CTC Test among Medicare-eligible mBC patient . Hereto hypothesis availability CTC information provide clinician important , timely information impact treatment decision , test . This study IDE-exempt since CELLSEARCH® CTC Test legally market device US , use accordance labeling .</brief_summary>
	<brief_title>Clinical Utility CTC Test Medicare-Eligible Metastatic Breast Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>Patient document ( histologically/pathologically confirm ) mBC diagnosis Patient least 65 year age time mBC diagnosis Patient male female Patient actively treat cancer center physician us plan use CTC test mBC patient lease every quarter . Patients breast cancer secondary primary</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>CELLSEARCH</keyword>
	<keyword>CTC</keyword>
	<keyword>metastatic breast cancer</keyword>
	<keyword>Registry</keyword>
	<keyword>mBC</keyword>
</DOC>